… antigens, showing similar booster responder rates against all three acellular pertussis
antigens … to reactogenicity and safety and to immunogenicity for all components of the vaccine. …

… research and evaluate their immunogenicity and safety. This assessment will provide valuable
insights into whether co-administration leads to any increased reactogenicity rates, which …

… lower IgG geometric mean concentrations for Hib, hepatitis B, diphtheria, and tetanus
antibodies. Local and systemic adverse events were similar between both groups at all time points. …

… less reactogenic pediatric acellular pertussis vaccine (diphtheria and tetanus toxoids and
acellular … single dose of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap…

… GSK’s hexavalent DTPa-HBV-IPV/Hib vaccine alone or co-administered with other pediatric
vaccines has a clinically acceptable safety and immunogenicity profile when used in infants …

… immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) and the
reduced-antigen-content diphtheria-tetanus-acellular … the safety and reactogenicity of RZV and …

… immunogenicity and safety of Tdap in PWWH compared with HIV-uninfected women. Antigen-…
, pertactin, fimbriae, diphtheria and tetanus were measured by electrochemiluminescence-…

… In the United States (US), the optimal recommended timing for the administration of one
dose of the reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine is …

… The primary immunogenicity endpoint was the proportion of participants achieving nasal …
at least one B pertussis antigen on day 29 or day 113. Reactogenicity was assessed up to 7 …

… the safety and immunogenicity of a recombinant acellular pertussis … in combination with
tetanus and diphtheria vaccines has … , acellular pertussis vaccines replaced the more reactogenic …